PDF
(Download)
|
- Bitter Orange (Citrus × aurantium)
- p-Synephrine
- Safety
|
Date:
06-28-2013 | HC# 031222-475
|
Re: Bitter Orange Is Found to be Safe in Healthy Adults after Intake for Two Months
Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60 day double-blind,
placebo-controlled safety study involving Citrus
aurantium [sic] (bitter orange)
extract. Food Chem Toxicol. May
2013;55:358-362.
Bitter orange (Citrus × aurantium) is a popular supplement among athletes and dieters,
primarily because of its constituent p-synephrine,
the primary protoalkaloid. The safety of p-synephrine
has not been established, though there have been no direct adverse event
reports made for it. The reason for concern is its structural similarity to ephedrine,
norepinephrine, and m-synephrine
(phenylephrine), which have been known to have detrimental cardiovascular
effects in some instances. Because bitter orange extract is often
consumed with other supplements, including caffeine, it is difficult to understand
what role bitter orange itself may have had in adverse events reported for the
combinations. Therefore, this double-blind, placebo-controlled study sought to
evaluate the safety of bitter orange, alone and in combination with the citrus
flavonoids naringin and hesperidin, in healthy adults.
Seventy-five healthy
adults (27-76 years of age; average age = 51.6 years; 15 males and 60 females),
with an average body mass index (BMI) of 30.8 kg/m2, were randomly
assigned to receive 2 doses daily for 60 days (to be taken before breakfast and
between 3 p.m. and 4 p.m.) of either 49 mg of p-synephrine alone; 49 mg of p-synephrine
with 576 mg of naringin and 100 mg of hesperidin; or placebo. The p-synephrine supplied for both treatment
groups was Advantra Z® (Nutratech, Inc.; West Caldwell, New Jersey);
the source of the hesperidin and naringin was not reported. Resting heart rate,
blood pressure, an 84-item Quality of Life Inventory, and a fasting 44-item
blood chemistry test were obtained at baseline.
Of the 75 subjects,
67 completed the study (13 males and 54 females); and attrition was equal in
all groups. No adverse events were reported by the participants at the end of
the study. There were no statistically significant changes from baseline in the
blood chemistry, systolic or diastolic blood pressure, resting heart rate,
heart, liver, kidneys, or quality of life in any of the groups. There was a
small, but statistically significant, difference in the increase of the average
resting heart rate between the combination group (3 beats per minute) and the p-synephrine-only (0.1 beat per minute)
and placebo groups (P < 0.05 for both). However, the differences were not
considered clinically significant; the placebo group average resting heart rate
unaccountably dropped 3.3 beats per minute.
This study was by far
the longest safety test of bitter orange alone, with past studies being no
longer than 1 day. In another study with a bitter orange extract that contained
47 mg of p-synephrine where heart
rates rose 11.4 beats per minute after 6 hours with an acute dose, the authors
argue that the increase happened at a time point too far after the half-life of
p-synephrine (2-3 hours) to be
attributed to it. In addition, other studies have shown that p-synephrine binds poorly to the
adrenergic receptors compared to norepinephrine, ephedrine, and m-synephrine, which could explain a lack
of potential adverse cardiovascular effects. This study indicates that a daily
dose of nearly 100 mg of p-synephrine
taken for up to 60 days is safe in healthy male and female adults. Efficacy
studies need to be done to determine if there would be any effects on weight
loss.
—Risa Schulman,
PhD
Peer
Reviewer's Comment:
A significant shortcoming
of this study was that plasma levels of p-synephrine
were not measured so as to correlate any pharmacodynamic effect(s) or the lack
thereof. The combination of p-synephrine
and caffeine is still a major concern among some health professionals and researchers, and this paper did not address this
issue.
|